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ABSTRACT 
On February 21, 2017, a European Respiratory Society research seminar held in Barcelona 
discussed how to best apply precision medicine to chronic airway diseases such as asthma and 
chronic obstructive pulmonary disease. It is now clear that both are complex and heterogeneous 
diseases, that often overlap and that both require individualised assessment and treatment. This 
paper summarises the presentations and discussions that took place during the seminar. 
Specifically, we discussed the need for a new taxonomy of human diseases, the role of different 
players in this scenario (exposome, genes, endotypes, phenotypes, biomarkers and treatable 
traits) and a number of unanswered key questions in the field. We also addressed how to deploy 
airway precision medicine in clinical practice today, both in primary and specialised care. 
Finally, we debated the type of research needed to move the field forward. 
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Many common human diseases are still diagnosed as if they are homogeneous entities, using criteria 
that have hardly changed in a century ... 
... the treatment for diseases that are diagnosed in this way is generic, with empiricism as its cornerstone 
KOLA and BELL [1] 
Introduction 
Asthma and chronic obstructive pulmonary disease (COPD) are the two most prevalent human 
airway diseases [2]. Surprisingly, well into the 21st century, they are still diagnosed following 
19th century approaches, which are fundamentally based on their clinical presentation and 
associated lung function abnormalities [3, 4], both of which are nonspecific. As a result, asthma 
and COPD are often treated similarly and, potentially, suboptimally [2, 5]. Furthermore, it can be 
questioned whether they are clearly separate entities or, alternatively, they may represent a 
heterogeneous spectrum of airway diseases that are linked to an array of biological deviations 
from what is considered a healthy state well adapted to its environment [1]. 
Recently, the term "precision medicine" has been proposed to define "treatments targeted to the 
needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial 
characteristics that distinguish a given patient from other patients with similar clinical 
presentations" [6]. Inherent in this definition is the "goal of improving clinical outcomes for 
individual patients and minimizing unnecessary side effects for those less likely to have a 
response to a particular treatment" [6]. In essence, therefore, the concept of precision medicine 
relates to the likelihood of responding (or not) to a given therapeutic intervention and/or 
suffering (or not) undesired side-effects (figure 1) [7]. In the context of chronic airways 
diseases, precision medicine can therefore be a promising strategy to improve their 
management [8]. Needless to say, physicians always try to be as precise as possible in relation to 
the needs of individual patients. The present step change, however, is based on the integrated 
assessment of the complex clinical and biological status of individual patients, which until 
recently was beyond reach [9]. 
On February 21, 2017, the European Respiratory Society convened a research seminar in 
Barcelona aimed at discussing how to best apply precision medicine to airway diseases and 
specifically to asthma and COPD. This perspective summarises the discussions and presents the 
conclusions and proposals from the seminar.  
Full presentations from the seminar can be downloaded from:  
http://www.ers-education.org/events/research-seminars/precision-medicine-in-airway-
diseases.aspx. 
Setting the stage, or where we are coming from  
We need a new taxonomy (classification] of human diseases 
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Human diseases are still classified on the basis of the principal organ system in which symptoms 
and signs manifest, and in which gross anatomical pathology and histopathology are correlated 
[10]. This so-called Oslerian paradigm, to honour Sir William Osier by whom it was first 
proposed, has been useful for clinical practice because it establishes a limited number of 
syndromic patterns to consider in daily practice. A syndrome is a set of medical signs and 
symptoms that commonly occur together and may be related to each other without necessarily 
tying them to a single identifiable pathogenesis [11]. Yet, this Oslerian paradigm over 
generalises pathological states (COPD and asthma, for instance, are terms that most probably 
include common as well as unique features), does not include susceptibility states or preclinical 
disease manifestations, and is of limited value to individualise precise diagnosis and therapy [12, 
13]. As pointed out in the introductory quote from KOLA and BELL [1], the taxonomy of human 
diseases is outdated and requires a profound reconsideration that leverages the most up-to-date 
and integrated biological knowledge we currently have [1, 10, 12, 14], 
The traditional, physiology-based classification system of airway disease that we use today does 
not represent the state of the art. We now know that there is a heterogeneous mix of distinct 
cellular and molecular mechanisms that go beyond the traditional physiological mechanisms of 
pulmonary disease, and that extrapulmonary comorbidities, psychosocial, behavioural and 
environmental factors significantly impact the health status and risk of morbidity and mortality 
of these patients. Therefore, there is an urgent need to rethink and disseminate the way we 
classify and manage airway diseases. 
 
FIGURE 1 Principles of precision medicine that illustrate the heterogeneity of any human disease 
and the potential impact of stratifying the population appropriately. Adapted from Chakma 
Justin [Journal of Young Investigators, 2009, Vol 16] 
 
The players: exposome, genes, endotypes, phenotypes, 
biomarkers and treatable traits 
Figure 2 illustrates the current multilevel understanding of the different biological players in 
this scenario. The interaction between our genetic background (genome) and the cumulative 
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environmental exposures an individual encounters throughout life (exposome) [15, 16], via a 
complex set of biological networks [20], determines the emergence of a number of cellular and 
molecular mechanisms that eventually contribute to the phenotype that we phenomenologically 
observe [20], this being a given disease or, more often, a specific clinical manifestation of a 
complex disease [17]. In this setting, several aspects require detailed discussion. 1) The 
traditional concept of a phenotype (an observable characteristic of an organism [20]) has been 
modified to provide a meaningful clinical framework. Hence, a clinical phenotype is "a single or 
combination of disease attributes that describe differences between individuals ... as they relate 
to clinically meaningful outcomes" [21]. It is their relationship with meaningful outcomes (e.g. 
symptoms, health status, death, exacerbations) that confer clinical utility to the concept; 
otherwise, it would remain a useless observational exercise. 2) The term endotype, a contraction 
of endophenotype, has been defined as "subtype of a disease defined functionally and 
pathologically by a molecular mechanism or by treatment response" [18]. This approach is 
radically different from the traditional Oslerian paradigm discussed earlier, which was (and still 
is) based mostly on the phenotypic presentation. Further, the beauty of the endotype concept is 
that, according to the definition of precision medicine presented above [6], it is a first step 
towards its implementation in clinical practice [7]. Yet, to date, it is still, by and large, a 
theoretical construct since we still do not understand the vast majority of biological mechanisms 
(i.e. endotypes) underlying different clinical presentations (i.e. phenotypes). 3) Given the key 
role played by biological networks in health and disease [22], novel analytical techniques (such 
as network analysis [23]) capable of integrating this multilevel complexity (exposome, genome, 
endotypes and phenotypes) are needed to unravel and understand the pathobiology of most 
human diseases, including chronic airway diseases. Such improved understanding should allow 
the identification and adequate validation of biomarkers (i.e. a biological, functional, imaging 
and/or clinical characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes or biological responses to a therapeutic 
intervention [19]). This is an absolute requirement to move towards precision medicine of 
airway diseases [7, 24]. 
Key questions in the management of airway diseases 
During the seminar, it was agreed that the following questions need to be answered (by 
appropriate research and/or consensus) to move precision medicine of airway diseases 
forward. 
Should we continue using the traditional diagnostic labels "asthma", "COPD", "bronchiolitis" 
and/or asthma-COPD overlap? Which assumptions go with these labels? What are the 
advantages/ disadvantages of using them? 
Diagnostic labels have many advantages: they are useful to discriminate grossly defined groups 
of patients, they form the basis for teaching students, they are easy to explain to patients, they 
are easy (but appropriate?) to use in interventional studies (i.e. randomised controlled trials 
(RCTs)) and they can be used to convince authorities to fund medications. In clinical practice, 
they are also useful to identify a syndrome (defined earlier) [11], but this will probably lead to 
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empirical (imprecise) management. The implicit assumption that goes with these traditional 
diagnostic labels is that these diseases are homogeneous in terms of their pathobiology and, 
therefore, that they need the same treatment in all patients. This is wrong, and if the labels are to 
remain, it needs to be clear that assumptions of pathophysiology should not be made. Thus, the 
labels represent the start of the assessment process, not the end. It was agreed that we need 
validated biomarkers (figure 2) that allow the clinician to build-up a clearer picture of the main 
drivers of morbidity, allowing provision of the right treatment, at the right time to the right 
person (figure 1). 
Would it be more helpful to deconstruct airway disease into components that can be measured 
and potentially modified (treatable traits)? 
As discussed above the terms "asthma" and "COPD" actually correspond to syndromes that 
comprise overlapping disorders/clinical phenotypes [25]. Participants in the seminar agreed 
that a treatable traits-based strategy was a first appropriate step towards the deconstruction of 
these terms into their individual treatable components and, as a result, towards precision 
medicine of chronic airway diseases. A treatable trait is a therapeutic target identified by 
"phenotype" or "endotype" recognition through validated biomarker(s) [8]. Table 1 lists a 
number of potential pulmonary, extrapulmonary and behavioural/lifestyle treatable traits to 
consider in patients with chronic airway diseases, and their specific therapeutic 
recommendations as per current international recommendations [3, 4]. Again, several aspects of 
this proposal require discussion. 1) Treatable traits are independent of the traditional, 
syndromic diagnostic "labels" used to date (i.e. they can occur in both patients with "asthma" or 
"COPD"). 2) Treatable traits can coexist in the same patient and can change within patients over 
time. These concepts are not captured adequately by the traditional phenotype concept (figure 
3), and are therefore important for the clinician to understand. 3) Finally, this treatable trait 
approach requires prospective validation, as discussed in detail later in this perspective. 
Identifying (currently) nontreatable traits (e.g. airway remodelling) would also be of relevance 
since it can foster specific research to fill the gap. 
Can available biomarkers identify different phenotypes or endotypes of airway disease? The 
serum level of α1antitrypsin in α1 antitrypsin deficiency is a well-established biomarker of a 
trait that may be treatable [27]. Other biomarkers that have been proposed in the context of 
chronic airway diseases include the following. 
1) A level of circulating eosinophils >3-4% or >300 cells-µL-1 appears to identify a 
subpopulation of patients with asthma or COPD, both when clinically stable as well as 
during an exacerbation of their disease, that are at higher risk of exacerbations and 
respond better to corticosteroid treatment [28-32], Furthermore, COPD patients with a 
persistent eosinophilic phenotype (about a third of the total COPD population [33]) have 
accelerated forced expiratory volume in 1 s decline, and a recent reanalysis of the 
ISOLDE study suggests that this is prevented by inhaled corticosteroid (ICS) treatment 
[34]. Finally, it is of note that there are different subtypes of eosinophils [35] which merit 
further research in patients with chronic airway diseases. 
2) Exhaled nitric oxide fraction (FeNo) is associated with eosinophilic airway inflammation 
and raised airway concentrations of type-2 cytokines (so called type-2 inflammation), 
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particularly interleukin-13 [36], It also appears to identify accelerated lung function 
decline in asthmatics [37], as do bronchial CD8, CD4 and CD3 cell infiltrates [38]. 
3) High IgE is often viewed as a treatable trait, although it is a disappointing biomarker of 
response to type-2 targeted treatments, including omalizumab [39-42], 
4) Airway bacterial colonisation and, eventually, changes in the airway microbiome can also 
be considered a treatable trait [43]. Sputum cultures and even sputum colour are useful 
biomarkers to detect airway bacterial colonisation and antibiotics are a validated 
treatment for this [44-47]. 
5) Persistent systemic inflammation occurs in a subset of patients with COPD [48] and 
asthma [49], and these patients have worse outcomes (in terms of mortality and 
exacerbations) [48]. A pilot study in patients with stable COPD that targeted systemic 
inflammation showed positive clinical benefits [50]. 
This is only the tip of the iceberg. We need more validated biomarkers to predict response to 
treatment (including adverse effects) (figure 1), monitor treatment effects and/or predict 
clinically relevant outcomes (mortality, exacerbations and lung function decline) [51-54]. 
Participants in the seminar agreed that by addressing these questions airway disease 
management will move into a new, more precise, better and safer era. To do so, however, it was 
also acknowledged that, in addition to a deeper knowledge of the biological basis of airway 
diseases, large, prospective, long-term interventional studies across the whole spectrum of 
airway diseases are needed, probably leveraging on new experimental designs ("master 
protocols") [55], which are discussed later in this perspective. 
FIGURE 2 Schematic of the relationships between the exposome and the genome [via complex 
biological networks], the emergence of endotypes and phenotypes, and the possibility of 
identifying them through validated biomarkers of treatable traits. For further explanation see 
the main text. 
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TABLE 1 List of potential pulmonary, extrapulmonary and behavioural/lifestyle treatable traits 
to consider in patients with chronic airway diseases 
Trait Treatment 
Pulmonary treatable traits  
Airway smooth muscle contraction Bronchodilators 
Eosinophilic airway inflammation Corticosteroids/Type 2 biologies 
Chronic sputum production Smoking cessation, macrolides, PDE4 inhibitors 
Bacterial colonisation Macrolides, tetracyclines 
Bronchiectasis Macrolides, tetracyclines, nebulised 
antibiotics/aminoglycosides 
Cough reflex hypersensitivity Gabapentin, P2X3, speech pathology intervention 
Chronic respiratory failure Oxygen/NIV/lung transplant 
Pulmonary hypertension Oxygen/NIV/lung transplant 
Emphysema Lung volume reduction/transplant 
Extrapulmonary treatable traits  
Rhinosinusitis Topical steroids/surgery 
Deconditioning Rehabilitation 
Cachexia Diet/physical activity 
Obesity Diet/physical activity/bariatric surgery 
Cardiovascular disease ACE inhibitors/diuretics/β-blockers 
Vocal cord dysfunction Speech pathology therapy 
Depression Cognitive and behavioural therapy 
Anxiety Anxiolytics 
Systemic inflammation Statins? 
Treatable behavioural/lifestyle factors  
Poor inhalation technique Education 
Nonadherence to treatment Reassurance/education/periodic check-up 
Smoking Cessation support 
Exposure to sensitising agents Avoidance/desensitisation 
Side-effects of treatments Treatment optimisation 
Polypharmacy Medication review 
Poor family and social support Family therapy education/self-management support 
PDE4: phosphodiesterase-4; P2X3: P2X3 receptor antagonist; NIV: noninvasive ventilation; ACE: 
angiotensin-converting enzyme.  
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Deployment of airway precision medicine in clinical 
practice, or where we are now  
THE PROBLEM 
Current clinical management of patients with chronic airway diseases is guided by national and 
international guidelines and recommendations, which, in turn, are based on group mean data 
from RCTs and do little to recognise individual heterogeneity, although they are slowly evolving 
in this direction [3, 4]. Despite this, it is fair to recognise that this guideline-based approach had 
progressively improved outcomes up until the past 15 years or so. Yet, in many developed 
countries improvements in outcome have stalled [56]. There have been no further decreases in 
hospitalisations or mortality despite steadily increasing pharmacy costs and increasing use of 
combination inhalers [57]. Real-life surveys repeatedly reveal that suboptimal control is 
common, and frequently show that potentially preventable factors occur in many deaths, 
hospitalisations and in most quality of life impairments [58]. This emphasises the need of better 
dissemination and implementation strategies, as well as novel and more effective (precise) 
management strategies. 
 
FIGURE 3 a] Pictorial representation of chronic obstructive pulmonary disease (COPDl 
heterogeneity. Each node represents one patient, and each colour represents different clinical 
characteristics, b] The approach to COPD complexity based on similar clinical presentations 
(colours], so-called phenotypes. c] Given that phenotypes can coexist in the same patient, an 
approach based on treatable traits has been proposed more recently [8]. Reproduced from [26] 
with permission. 
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ARE WE READY TODAY? 
The challenge is to develop simple algorithms that enable the identification of potential treatable 
traits, which may be contributing to poor respiratory health in a patient with airway disease 
(table 1). And, yes, despite the uncertainties discussed earlier surrounding endotypes, 
phenotypes and biomarkers, there are a few relatively simple things that we can do today that 
will probably improve the management of patients with chronic airway diseases. As shown in 
figure 4, the first proposed step would be to determine if the patient "really" has airway disease 
[8]. To answer this question a simple strategy that combines standard clinical history, 
assessment of potential risk factors for airway diseases (smoking, allergies, occupation, family 
history and early life events) and measurement of spirometry, FeNO and blood eosinophils can 
be conceived, both in primary and specialised care. The results of this assessment may 
determine the probability (high or low) of airway disease being present. If there is a high 
probability of airway disease, therapy should be based upon the treatable traits present in that 
individual patient (table 1), which, importantly, are not mutually exclusive [8]. By contrast, if the 
clinical history is atypical, no risk factors of airway disease can be identified and the results of 
these tests are normal, alternative diagnoses should be considered [8]. Needless to say, once the 
patient has been diagnosed and treated for airway disease according to this treatable traits 
strategy, follow-up needs to consider (as recommended by current international 
recommendations [3, 4]): adherence with treatment, inhalation technique, response to therapy 
[59], and risk of future events [60]. The concept of "control" has been basically applied to 
asthma, but some recent alternatives have also been proposed for COPD [61]. Although there is 
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evidence to support the investigation and management of the individual components of this 
strategy, this prototype schema (and future modified versions) will need to be assessed by RCTs 
to provide scientific evidence of their effectiveness and safety in clinical practice. Likewise, 
alternative systems by which precision medicine might be delivered in clinical practice should 
also be investigated as a priority. Eventually, complex bio-clinical traits will need to be 
approached by machine learning and artificial intelligence, which provide very powerful 
computational models for potentially predicting clinical course and treatment responses [62, 
63], 
PRIMARY VERSUS SPECIALISED CARE? 
The majority of new diagnoses and the routine management of mild and moderate chronic 
airway diseases occur in primary care. Although the impetus to precision medicine has come 
from difficult to control airway diseases, typically seen in tertiary care centres, the concepts of 
complexity and heterogeneity are equally relevant in patients with milder disease treated in the 
community, because individual patients are different and the reasons for poor control are 
heterogeneous. The era of precision medicine of airway diseases is dawning, and primary care 
should be involved. Individualised therapy based on assessment of the two dominant treatable 
traits, eosinophilic airway inflammation and airflow limitation, would be well within the scope 
of nonspecialist clinicians and would be an important step in this direction. 
FIGURE 4 Proposed diagnostic strategy for an adult with symptoms, signs or events suggestive of 
airway disease (without any further "traditional diagnostic labelling"]. For further explanation 
see the main text. FeNO: exhaled nitric oxide fraction. #: smoking, allergies, sputum production, 
occupation, lung development and growth; ¶: see tables 1-3 in [8]; +: see tables 2 and 3 in [8]. 
Reproduced and modified from [8] with permission. 
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How to move the field forward through research Prior 
experiences 
SINGLE BIOMARKER STUDIES 
Early trials of targeted management of chronic airway diseases focused on single inflammatory 
biomarkers. RCTs conducted using sputum eosinophil counts as a biomarker to guide treatment 
decisions showed reduced exacerbations versus guideline-based therapy both in asthma [64] 
and COPD [65]. Other trials used FeNO to guide treatment decisions and a meta-analysis of these 
studies indicated superior outcomes over an approach focused on asthma symptoms [66]. 
Finally, the use of bronchial hyperreactivity as a biomarker also showed efficacy and lead to a 
more effective control of asthma while alleviating chronic airways inflammation, indicating that 
the concept goes beyond inflammatory markers [67]. All in all, these studies support the 
paradigm of precision medicine when treatment is targeted to a specific pathway. Importantly, 
they show the benefit of a precision medicine approach across the asthma severity spectrum. 
This means that precision medicine of airway disease need not be restricted to severe or 
refractory disease (as it has been in current guidelines), but can benefit people with mild disease 
as well [68]. 
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MULTIPLE BIOMARKER STUDIES 
Precision medicine, however, extends beyond a single biomarker/treatable trait, since an 
individual patient can have multiple potentially treatable traits. To date, only a few studies have 
attempted to apply a multidimensional assessment followed by individualised management in 
patients with chronic airway diseases. MCDONALD et αl. [50] tested this strategy in a proof-of-
concept study in a COPD population, where the multidimensional assessment involved the 
evaluation of airways, comorbidities, risk factors and behavioural traits, as well as the 
measurement of several systemic inflammatory markers ("inflammometry"). The results 
showed that this precision medicine approach led to a highly clinically significant improvement 
in health status [50]. These observations have been reproduced very recently in patients with 
severe asthma [69]. While the results of these trials are promising, we acknowledge that this is a 
complex approach to trial design and execution that raises questions in terms of whether the 
observed effects are related to any one intervention in particular or are the result of a "stacked 
approach", that is additive effects of multiple interventions [55]. Thus, in the future different 
study designs need to be considered, as discussed later in this perspective [55]. Likewise, it is 
conceivable that precision medicine will more and more rely on the fast, on-site ("point of care") 
assessment of multiple biomarkers derived from high-throughput "omic" platforms [70-72]. 
A treatable traits study proposal 
There was consensus that the treatable traits strategy [8] was a potentially feasible approach to 
deploy precision medicine of airway diseases in clinical practice. However, there was also 
consensus that it required formal, prospective and controlled validation, most probably in an 
international multicentre, multicomponent interventional setting [55]. However, it was 
acknowledged that this will be complex, so the following issues were specifically discussed. 
TRIAL DESIGN 
Traditional RCTs are designed to test a single treatment in a homogeneous population. As a 
result, only a small proportion of patients with asthma or COPD are included in the major RCTs 
for asthma or COPD that, importantly, form the basis of current guideline recommendations 
despite their reduced generalisability [58, 73]. Furthermore, this approach is not adequate to 
test multicomponent interventions in heterogeneous populations. Likewise, it is not an effective 
way to test a biomarker driven treatment algorithm in airway disease [74], 
The so-called "master protocols" leverage from novel experimental designs and are better suited 
for these purposes [55]. A master protocol has one overarching protocol designed to answer 
multiple questions, which may involve one or more interventions in multiple diseases or a single 
disease, as defined by current disease classifications, with multiple interventions, each targeting 
a particular biomarker-defined population or disease subtype [55]. There are several types of 
master protocols, including the so-called "umbrella", "basket" and "platform" trials [55, 75, 76]. 
"Umbrella" trials study multiple targeted therapies in the context of a single disease; "basket" 
trials study a single targeted therapy in the context of multiple diseases or disease subtypes; and 
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"platform" trials (figure 5) study multiple targeted therapies in the context of a single disease, 
with therapies allowed to enter or leave the platform on the basis of an agreed decision 
algorithm [55]. At the seminar, it was agreed that, in order to test the efficacy and safety of a 
treatable traits strategy for the management of airway disease in practice, a platform trial design 
(figure 5) would be probably adequate, because it is precisely designed to identify the optimal 
"set of treatments" in conditions where management involves multiple therapies delivered 
concurrently, which have the potential to have independent or interacting effects on outcome. 
Table 2 contrasts the main characteristics of a platform trial versus traditional RCTs. However, it 
was also acknowledged that the design and statistical methods involved in a platform trial are 
complex, and that they would require appropriate knowledge and expertise. Finally, it was 
agreed that such a trial will create the opportunity to generate a multicentre biobank [78] to 
store biological samples for future studies. 
INTERVENTION(S) 
A crucial component of the study will be the standardisation of both the multidimensional 
assessment and a tailored treatable traits plan. This should be greatly facilitated by a care 
coordinator, as the proposed intervention is a treatable traits strategy, rather than an individual 
single component intervention that targets a specific trait. As such it is likely to require multiple 
health behaviour changes from the patients' perspective and significant coordination from a 
healthcare perspective. The care coordinator or case manager will ensure that the overall 
treatment plan is implemented. Early trials with a similar design support this approach [50, 69]. 
Complex interventions in healthcare comprise a number of separate elements which seem 
essential for the proper functioning of the intervention, although "the" active ingredient(s) of 
the intervention is (are) often difficult to identify [55]. It is possible that the "stacked" approach, 
that is multiple traits being treated simultaneously with a measurable and additive benefit to 
each intervention, leads to a larger than expected improvement [79]. In addition, the impact of 
treating multiple traits may have effects not only on the intended outcome(s) but may also 
benefit multiple other domains. For example, treating obesity in COPD not only improves body 
composition, but also improves exercise tolerance, cardiovascular outcomes and depression 
[79]. This, combined with pharmacotherapy or pulmonary rehabilitation, may in fact increase 
the final effect size. A large trial should therefore be able to have enough power to perform 
regression/ mediation analysis of subgroups receiving particular interventions to determine 
what it is that is having the greatest impact. A final consideration that emerged during the 
discussion of this particular topic was that "no intervention" is, in fact, "an intervention" and this 
should be actually considered when designing the appropriate studies and subgroup analyses. 
For instance, it may be of interest to identify individuals in whom the active treatable traits 
strategy resulted in a particular treatment decision that would have been different with "usual 
care", and where possible compare outcomes with similar individuals from the control group 
treated using diagnosis-driven guidelines. 
OUTCOMES 
The choice of outcome measure(s) in a treatable traits trial is also of paramount importance. The 
primary outcome in such a study should be valid and responsive to each of the treatments used. 
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Established outcomes, such as severe exacerbations, hospital admissions or death, are likely to 
be the preferred primary "hard" outcomes, particularly in high-risk groups. However, because 
the interventions will target different pathways, it is also necessary to have trait-specific 
outcomes that demonstrate efficacy of the intervention on each pathway. For example, a type 2 
anti-inflammatory intervention needs to show benefit in reducing type 2 inflammation, such as 
eosinophils or FeNO. However, this may not be suitable as the primary study outcome, since it 
would not be responsive to non-type 2 traits, such as treatment for depression. In this situation, 
a more global outcome measure is needed, and health status should not be dismissed albeit it is 
usually considered a "soft" outcome. Health status is the single outcome that best encompasses 
the overall impact of disease on an individual's life. Therefore, it is of high importance from the 
patient perspective, particularly in light of previous data that indicates that for each additional 
trait there is a clinically significant decrement to quality of life [80]. Perhaps a composite 
outcome may be ideal, incorporating health status with other outcomes. Also, it cannot be 
excluded that, in addition to such measures of individual well-being, particular biomarkers or 
biomarker profiles can provide complementary information on therapeutic outcome of a 
treatable traits strategy. 
Finally, provided the results of the trial are positive, other outcomes that will facilitate its 
eventual deployment in clinical practice relate to the inclusion of: 1) health economists to design 
and execute a robust health economics analysis (cost-effectiveness analysis) in the context of 
value-based healthcare; 2) consumers in the development of the study, since it is likely to be 
complex and this advice may lead to better patient adherence; and 3) some sort of qualitative 
evaluation to determine patient and clinician experiences and attitudes surrounding the 
treatable traits approach (i.e. acceptability, adoption, appropriateness and sustainability), which 
can help develop a better understanding of the intervention characteristics. 
FIGURE 5 Evolution of a platform trial over time. In this example, three interventions (A, B, and 
C] and their combinations (AB, BC, and AC] are assessed in a population of patients that includes 
three subtypes of the disease (indicated by the colours blue, red and yellow], a] When the study 
is started, randomisation is balanced between all possible treatments and all patient subtypes 
are treated similarly. After a period of time it appears that BC is having a greater effect than the 
other treatments and, to a lesser extent, so are B, C and AC. Thus, subsequent randomisation 
enriches the number of patients assigned to receive BC (indicated by the larger font] as well as 
B, C and AC (panel b). c] After the trial continues further, analysis reveals that treatment A and 
its combinations are not effective in any subgroup and the "yellow" subgroup is not effectively 
treated in any arm, so patients are no longer randomised to receive any combination including 
treatment A and the "yellow" subgroup is discontinued from further enrolment. At the end of the 
trial (not shown in the figure] the combination treatment BC may graduate from the trial, based 
on evidence of benefit in the "blue" subtype of disease, to be recommended for clinical use or for 
further evaluation in a separate phase III trial. Reproduced from [75] with permission. 
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TABLE 2 Comparison of the main features of traditional versus platform randomised controlled 
trials (RCTs) 
 Traditional RCTs Platform RCTs 
Intervention Single public health or therapeutic Various interventions or combinations of 
 intervention interventions 
New treatments might be added during the trial 
Population Homogeneous (high risk] Homogeneous or heterogeneous Subgroups 
defined by clinical phenotypes or biomarkers; 
might be changed over time 
Allocation Fixed randomisation Response-adaptive randomisation 
Duration Finite with option of extending Potentially long term, extended if novel 
treatments 
 duration of follow-up need assessment 
Stopping Trial might be stopped early for Individual treatments might be stopped, but trial 
rules success, failure or futility might be continued with new interventions 
Statistics Standard in-house methods Complex, Bayesian, continuous analysis, often 
needing a specialised statistical team 
Funding Government or pharmaceutical Scope for sponsorship from both government and 
 company sponsorship pharmaceutical companies 
Collaboration Single centre or multiple centres, similar 
populations 
Multicentre, international, from diverse 
populations 
Reproduced from [77] with permission.  
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There was unanimous agreement in the seminar that to improve the current management of 
complex airway diseases like asthma and COPD a precision medicine approach was required, 
and that to achieve this in practice the best available alternative was the one based on the 
treatable traits strategy. However, this consensus needs prospective, formal validation. Several 
key aspects of such a trial, including design (platform trial), interventions (multidimensional 
assessment and tailored treatable trait intervention) and outcomes (hard and soft), were 
discussed. We now hope that independent umbrella organisations such as the European 
Respiratory Society take on the challenge of promoting and facilitating the prospective testing of 
whether the adoption of a treatable traits strategy as a first step toward precision medicine of 
airway diseases improves the outcomes and safety of these patients. The European Organisation 
for Research and Treatment of Cancer (http://www.eortc.org) does exactly this for cancer. As 
one of the anonymous reviewers of this paper (to whom we are thankful) suggested, we can do 
something similar (EORTA: a European Organization for Research and Treatment of Airway 
diseases) to generate concerted actions to investigate novel treatments and strategies in COPD, 
asthma, asthma-COPD overlap and bronchiectasis. All of the participants in the seminar (listed in 
the Acknowledgements section) certainly look forward to doing so. 
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